PCR Devices Industry was valued at USD 2.85 Billion for the year 2018. PCR Devices Industry is further expected to grow at a CAGR of 8.9% from 2018 to reach USD 5.20 Billion by the year 2025. polymerase chain reaction process are offering high growth opportunities for players active in the global PCR Devices industry. However, lack of technically skilled professionals, unfavorable reimbursement scenario, and high cost of dPCR devices and are some of the key factors hampering the growth of this industry during the forecast period.
The global PCR Devices industry is poised to witness an increasing demand growth during the forecast period. This is expected to be driven by major factors such as expansion in its application areas and procedural benefits offered by PCR Devices (such as real-time process monitoring, low reagent consumption, and device miniaturization, among others), increasing investments in gene therapy and government support for product R&D, rise in number of diagnostic centers & hospitals, and increasing investments and availability of funds for PCR-based research.
Major market players in PCR Devices Industry are Abbott. (US), BD(US), F. Hoffman-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), QIAGEN ( Germany), Thermo Fisher Scientific Inc.(US), Danaher (US), Merck KGaA (Germany), Promega Corporation (US), Takara Bio, Inc (Japan), Biomérieux S.A. (France), Fluidigm (US), Siemens (Germany), Enzo Life Science, Inc (India), Analytik Jena AG (Germany), SYGNIS Pharma AG(Germany ), LGC Limited (UK), RainDance Technologies, Inc (US) Affymetrix Inc (US ).
By End User